| |
DanielAdewunmiFirstEssay 4 - 20 Feb 2023 - Main.EbenMoglen
|
|
META TOPICPARENT | name="FirstEssay" |
| | As a result, there is currently a Congressional proposal that has been tabled entitled the Promising Pathway Act. This act is intended to combat the very issues expounded upon in this narrative to increase the feasibility of clinical testing. However, political maneuvers have resulted in the act being tabled off, potentially dead in the water. This intersection of current legal standards, policy, and medical research have created an obstacle in combatting an illness that has touched myself and my family directly. It is an obstacle that I hope to see overcome, one that I eagerly seek guidance regarding manners in which to approach the issue, as I find myself in an environment in which instructors and mentors may have valuable insights. | |
> > |
I'm so sorry, Daniel. I lost my father to gliobastoma, and so we have shared some of life's most disturbing experiences.
As you may have seen among the research docs, the loss of a sibling is a surprisingly frequent motivator in setting people on the lifetime path of research against the disease that caused the death. This draft suggests that you might be inclined by your own tragic experience to develop your practice along lines that intersect in the funding and regulatory approval of pediatric oncology R&D. In that case, the route to improvement is to bring the draft from the past into the future, from showing how you came by the mission to describing how you plan to educate yourself to perform it.
The first step is to outline what you need to learn, the catalog of questions that represent what you don't know about your future practice. The next is to define the network you need to build, that is, the people you need to meet. Along the way, compiling those questions involves discovering sources, reading about both what and who. That means building your own learning infrastructure, from bibliography to Rolodex. Your next draft should be about how you intend to do that.
| |
You are entitled to restrict access to your paper if you want to. But we all derive immense benefit from reading one another's work, and I hope you won't feel the need unless the subject matter is personal and its disclosure would be harmful or undesirable.
To restrict access to your paper simply delete the "#" character on the next two lines: |
|
|
|
This site is powered by the TWiki collaboration platform. All material on this collaboration platform is the property of the contributing authors. All material marked as authored by Eben Moglen is available under the license terms CC-BY-SA version 4.
|
|
| |